Hepatitis E Virus Infection in Pediatric Oncology

Authors :: Anna, Lenglart
Céline, Chappé
Isabelle, Grulois
Françoise, Hervé
Virginie, Gandemer
Guillaume, Robert
CHU Pontchaillou [Rennes]
Etablissement français du sang [Rennes] (EFS Bretagne)
Institut de Génétique et Développement de Rennes (IGDR)
Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Université de Rennes - Faculté de Médecine (UR Médecine)
Université de Rennes (UR)
Source :: Journal of Pediatric Hematology/Oncology, Journal of Pediatric Hematology/Oncology, 2023, 45 (1), pp.E150-E153. ⟨10.1097/MPH.0000000000002539⟩
Publication Year :: 2022
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2022.
Abstract: International audience; Background:In the 2016 ESPGHAN recommendations on how to deal with hepatitis E virus infection in immunocompromised children, patients treated with chemotherapy were not specifically mentioned. Observations:Two teenagers treated with chemotherapy for acute leukemia and medulloblastoma, respectively, were diagnosed with hepatic cytolysis. After numerous investigations hepatitis E was found, limiting the good progress of the chemotherapy treatment. Conclusion:In the case of liver cytolysis in immunocompromised children treated with chemotherapy, hepatitis E virus infection has to be promptly diagnosed.